Literature DB >> 34306186

Efficacy of small-dose ganciclovir on cytomegalovirus infections in children and its effects on liver function and miR-UL112-3p expression.

Qingxiu Wang1, Wenzeng Zhou2, Bin Wang3, Guoyun Qin4, Feng'Ai Liu5, Dexiang Liu6, Tengteng Han2.   

Abstract

The aim of the study was to explore the efficacy of small-dose ganciclovir on cytomegalovirus infections as well as its effects on the liver function and miR-UL112-3p of children. A total of 141 children infected with cytomegalovirus admitted to the Affiliated Hospital of Weifang Medical University from May 2015 to August 2017 were enrolled, of which 74 children were treated with small-dose ganciclovir as an observation group (Obs group), and the rest were treated with conventional-dose ganciclovir as a control group (Con group). The two groups were compared in efficacy after treatment, changes of liver function indexes [total bilirubin (TB), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)] and miR-UL112-3p before and after treatment, and adverse reactions after treatment. A receiver operating characteristic (ROC) curve was drawn to analyze the value of miR-UL112-3p in predicating efficacy on cytomegalovirus infections in children, and Pearson's correlation analysis was carried out to analyze the correlation between miR-UL112-3p expression and TB, ALT and AST. The MV-DNA level between the two groups after treatment was compared. The two groups showed no significant difference in efficacy and adverse reactions (both P>0.05), and before treatment, there was also no significant difference between the two groups in miR-UL112-3p, TB, ALT, and AST, while after treatment, both groups showed lower levels of miR-UL112-3p, TB, ALT, and AST, and the Obs group showed significantly lower levels thereof than the Con group (all P<0.05). In addition, the area under the curve (AUC), specificity, and sensitivity of miR-UL112-3p in the ROC curve of the Obs group were 0.866, 73.77 and 84.62%, respectively, while the AUC, specificity, and sensitivity of the ROC of the Con group were 0.837, 75.44, and 90.00%, respectively. Furthermore, miR-UL112-3p was positively correlated with TB, ALT, and AST, respectively. The CMV-DNA level in the Obs group was lower than that in the Con group, but the difference was not significant, and the level of CMV-DNA was positively correlated with that of miR-UL112-3p. In conclusion, small-dose ganciclovir can better improve the liver function of the children, and downregulate miR-UL112-3p in them. The AUC, specificity, and sensitivity of miR-UL112-3p for predicting the efficacy of small-dose ganciclovir were 0.866, 73.77 and 84.62%, respectively, and the AUC, specificity, and sensitivityfor predicting the efficacy of conventional-dose ganciclovir were 0.837, 75.44 and 90.00%, respectively.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  cytomegalovirus infections in children; ganciclovir; liver function; miR-UL112-3p; small dose

Year:  2021        PMID: 34306186      PMCID: PMC8281003          DOI: 10.3892/etm.2021.10344

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  29 in total

1.  Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.

Authors:  Shambhu Aryal; Shalika B Katugaha; Adam Cochrane; Anne Whitney Brown; Steven D Nathan; Oksana A Shlobin; Kareem Ahmad; Lauren Marinak; Jessica Chun; Margaret Fregoso; Shashank Desai; Christopher King
Journal:  Transpl Infect Dis       Date:  2019-09-18       Impact factor: 2.228

Review 2.  [Modern ethiotropic chemotherapy of human cytomegalovirus infection: clinical effectiveness, molecular mechanism of action, drug resistance, new trends and prospects. Part 1.]

Authors:  V L Andronova
Journal:  Vopr Virusol       Date:  2018

Review 3.  MicroRNAs Regulating Reactive Oxygen Species in Cardiovascular Diseases.

Authors:  Yao-Yu Gong; Jiang-Yun Luo; Li Wang; Yu Huang
Journal:  Antioxid Redox Signal       Date:  2017-11-07       Impact factor: 8.401

4.  Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.

Authors:  H Y Ju; H J Kang; C R Hong; J W Lee; H Kim; K D Park; H Y Shin; J D Park; E H Choi; H J Lee; H S Ahn
Journal:  Transpl Infect Dis       Date:  2016-06-09       Impact factor: 2.228

5.  Congenital cytomegalovirus infection inducing non-congenital sensorineural hearing loss during childhood; a systematic review.

Authors:  Maria Riga; George Korres; Pantelis Chouridis; Stephanos Naxakis; Vasilios Danielides
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2018-10-04       Impact factor: 1.675

6.  Human Cytomegalovirus miR-UL112-3p Targets TLR2 and Modulates the TLR2/IRAK1/NFκB Signaling Pathway.

Authors:  Igor Landais; Chantel Pelton; Daniel Streblow; Victor DeFilippis; Shannon McWeeney; Jay A Nelson
Journal:  PLoS Pathog       Date:  2015-05-08       Impact factor: 6.823

7.  Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients.

Authors:  Yi Pan; Nan Wang; Zhenxian Zhou; Hongwei Liang; Chaoyun Pan; Dihan Zhu; Fenyong Liu; Chen-Yu Zhang; Yujing Zhang; Ke Zen
Journal:  Sci Rep       Date:  2016-03-10       Impact factor: 4.379

8.  Distinct expression profile of HCMV encoded miRNAs in plasma from oral lichen planus patients.

Authors:  Meng Ding; Xiang Wang; Cheng Wang; Xiaoshuang Liu; Ke Zen; Wenmei Wang; Chen-Yu Zhang; Chunni Zhang
Journal:  J Transl Med       Date:  2017-06-07       Impact factor: 5.531

9.  Primary cytomegalovirus infection in immunocompetent adults in the United States - A case series.

Authors:  Nathanial Nolan; Umme-Aiman Halai; Hariharan Regunath; LPatrick Smith; Christian Rojas-Moreno; William Salzer
Journal:  IDCases       Date:  2017-11-10

10.  Associations between patient clinical characteristics and the presence of cytomegalovirus DNA in the bronchoalveolar lavage fluid of children with recurrent wheezing.

Authors:  Huiming Sun; Shuxiang Li; Yongdong Yan; Zhengrong Chen; Yuqing Wang; Chuangli Hao; Wei Ji
Journal:  BMC Infect Dis       Date:  2018-09-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.